Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Sees Significant Drop in Short Interest

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) was the recipient of a large decline in short interest in the month of May. As of May 15th, there was short interest totaling 670,614 shares, a decline of 77.9% from the April 30th total of 3,038,967 shares. Approximately 6.4% of the company’s shares are sold short. Based on an average daily trading volume, of 2,410,748 shares, the days-to-cover ratio is presently 0.3 days.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Warberg Asset Management LLC acquired a new stake in shares of Calidi Biotherapeutics in the third quarter valued at $28,000. Virtu Financial LLC purchased a new stake in Calidi Biotherapeutics in the fourth quarter valued at approximately $25,000. Geode Capital Management LLC boosted its holdings in shares of Calidi Biotherapeutics by 41.7% in the fourth quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock valued at $49,000 after acquiring an additional 12,334 shares during the period. Finally, DRW Securities LLC purchased a new position in shares of Calidi Biotherapeutics during the fourth quarter worth approximately $173,000. Hedge funds and other institutional investors own 12.53% of the company’s stock.

Calidi Biotherapeutics Trading Down 3.2%

Shares of NYSEAMERICAN:CLDI traded down $0.01 during midday trading on Friday, reaching $0.18. 1,264,992 shares of the company’s stock were exchanged, compared to its average volume of 2,611,033. The firm’s 50 day simple moving average is $0.23 and its two-hundred day simple moving average is $0.78. The stock has a market cap of $3.55 million, a price-to-earnings ratio of -0.04 and a beta of 1.38. Calidi Biotherapeutics has a fifty-two week low of $0.16 and a fifty-two week high of $19.20. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.92 and a quick ratio of 1.92.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.43) earnings per share for the quarter.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.